Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902072 | 1.00 | GRM8 (0.50) | GRM8GRM4CES2CES1KIF11 | |
| SCHEMBL18125936 | 1.00 | GRM8 (0.50) | GRM8GRM4CES2CES1KIF11 | |
| SCHEMBL23182220 | 0.84 | CES2 (0.50) | GRM8GRM4CES2CES1ACP3 | |
| SCHEMBL953432 | 0.84 | CES2 (0.50) | GRM8GRM4CES2CES1KIF11 | |
| SCHEMBL13527786 | 0.82 | HSD17B10 (0.61) | GRM8GRM4HSD17B10TDP1MEN1 | |
| SCHEMBL5597212 | 0.81 | PDPK1 (0.49) | GRM8GRM4CES2CES1KIF11 | |
| SCHEMBL11516733 | 0.80 | NR1H4 (0.47) | GRM8GRM4KIF11HSD17B10TDP1 | |
| SCHEMBL5018968 | 0.79 | NR1I2 (0.53) | GRM8GRM4CES2CES1KIF11 | |
| SCHEMBL8430347 | 0.79 | CES2 (0.50) | GRM8GRM4CES2CES1KIF11 | |
| SCHEMBL4967991 | 0.79 | NR1I2 (0.53) | GRM8GRM4CES2CES1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391779-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| EP-4196480-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-06-21 | — | — | EP | disclosed |
| CN-115989341-A | Method for manufacturing structure with conductive pattern | 旭化成株式会社 | 2023-04-18 | — | — | CN | disclosed |
| CN-115968113-A | Method for manufacturing structure with conductive pattern, kit and system | 旭化成株式会社 | 2023-04-14 | — | — | CN | disclosed |
| CN-115956080-A | Bicyclic compounds, compositions containing them and their use | 贝达药业股份有限公司 | 2023-04-11 | — | — | CN | disclosed |
| WO-2022085461-A1 | METHOD FOR MANUFACTURING CONDUCTIVE PATTERN-PROVIDED STRUCTURE | 旭化成株式会社 | 2022-04-28 | — | — | WO | disclosed |
| US-20200407395-A1 | CHIRAL PEPTIDES | RA CAPITAL HEALTHCARE FUND, L.P. | 2020-12-31 | — | — | US | disclosed |
| US-10870678-B2 | Chiral peptides | ARCUATE THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| WO-2020214518-A1 | METHODS OF TREATING RENAL CONDITIONS USING PEPTIDES THAT IMPROVE MITOCHONDRIAL FUNCTION | ARCUATE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-3668886-A2 | TAU AGGREGATION PEPTIDE INHIBITORS | Adrx, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-1345918-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | disclosed |
| US-4155905-A | 6-Substituted penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1979-05-22 | — | — | US | disclosed |
| US-4077967-A | 6-Substituted penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4061629-A | 6-Amino-6-arylthio penicillanic acids and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4061851-A | 7-Amino-7-arylthio cephalosporins | E. R. SQUIBB & SONS, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4029669-A | 6-Benzalimino-6-arylthio penicillanic acids and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1977-06-14 | — | — | US | disclosed |
| US-4026886-A | 7-Acyl-7-arylthiocephalosporins | E. R. SQUIBB & SONS, INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-3965093-A | 6-Arylthio penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3954744-A | ANTIBACTERIAL | E. R. SQUIBB & SONS, INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391779-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | CYP11B2, CYP11B1, CYP27A1 | GRM8 4317/4885GRM4 4253/4885CES2 478/4885 |
| US-20200407395-A1 | CHIRAL PEPTIDES | IAPP, VIP, NPPA | GRM8 2589/4885GRM4 3309/4885CES2 3098/4885 |
| US-10870678-B2 | Chiral peptides | IAPP, VIP, NPPA | GRM8 2589/4885GRM4 3309/4885CES2 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.